Alpha-Synuclein Immunization for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies, characterized by alpha-synuclein aggregation and Lewy body formation, lack effective therapeutic options for preventing or ameliorating neuropathology and cognitive impairment.
Innovation Solution
Administration of alpha-synuclein or its fragments, or antibodies targeting specific epitopes, to induce an immunogenic response, thereby reducing the number of inclusions in the brain and improving motor characteristics and cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alpha-synuclein aggregation and Lewy body formation are allowed to proceed naturally, then the disease progresses with motor deterioration and cognitive impairment, but no effective therapeutic intervention is available
Solution Approach 1:
The patent utilizes the harmful alpha-synuclein protein itself as an immunogen to generate therapeutic antibodies. By administering alpha-synuclein or its fragments, the body's immune system produces antibodies that specifically target and neutralize the pathological aggregates, converting the harmful substance into a beneficial therapeutic agent
Solution Approach 2:
The patent employs preventive immunization strategies where alpha-synuclein-based vaccines are administered before the full development of symptomatic disease. This preliminary action aims to establish protective antibody levels that can prevent or delay the formation of Lewy bodies and associated neuropathology
2Object-generated harmful factors
If immunogenic agents targeting alpha-synuclein are administered, then antibody production increases and aggregation is reduced, but the complexity of the therapeutic regimen increases
Solution Approach 1:
The patent identifies and utilizes specific epitopic fragments of alpha-synuclein (such as residues 1-40, 70-140, and other defined regions) as immunogens. This segmentation allows for targeted antibody production against specific pathological regions, potentially simplifying the therapeutic approach by focusing on key epitopes rather than requiring whole-protein immunization
Solution Approach 2:
The patent employs adjuvants as intermediary substances to enhance and modulate the immune response to alpha-synuclein immunogens. These adjuvants facilitate antibody production and can influence the quality and duration of the immune response, simplifying the overall therapeutic regimen by incorporating a single well-formulated vaccine composition
3Ease of operation
If antibodies targeting alpha-synuclein are administered, then Lewy body formation is reduced and motor function improves, but the availability of effective treatments remains limited
Solution Approach 1:
The patent employs active immunization strategies where the patient's own immune system is harnessed to produce therapeutic antibodies against alpha-synuclein. This self-service approach eliminates the need for continuous administration of exogenous antibodies, providing a sustainable long-term treatment that improves motor function and delays disease progression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively induces an immune response that decreases alpha-synuclein aggregation, reduces Lewy body formation, and improves symptoms in transgenic mouse models, offering a potential therapeutic regime for these diseases.
Implementation Method 1
Administration of alpha-synuclein or its fragments, or antibodies targeting specific epitopes, to induce an immunogenic response
Data Source
AI summary
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.